Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.
Company profile
Ticker
NBTX
Exchange
Website
CEO
Laurent Levy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
NBTX stock data
Latest filings (excl ownership)
6-K
Voting Rights and Shares Capital of the Company
11 Jan 23
6-K
Current report (foreign)
27 Dec 22
6-K
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
21 Dec 22
6-K
Voting Rights and Shares Capital of the Company
8 Dec 22
6-K
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
15 Nov 22
6-K
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
14 Nov 22
6-K
Current report (foreign)
10 Nov 22
6-K
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
9 Nov 22
6-K
NANOBIOTIX Voting Rights and Shares Capital of the Company
8 Nov 22
6-K
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
2 Nov 22
Financial summary
| Quarter (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
Institutional ownership, Q3 2022
18.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 6 |
| Opened positions | 0 |
| Closed positions | 1 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 37.08 mm |
| Total shares | 6.53 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Artal International S.C.A. | 3.07 mm | $24.86 mm |
| Baillie Gifford & Co | 1.40 mm | $4.91 mm |
| Perceptive Advisors | 1.06 mm | $3.75 mm |
| Artal | 1.00 mm | $3.54 mm |
| UBS UBS Group AG - Registered Shares | 3.04 k | $11.00 k |
| Activest Wealth Management | 283.00 | $1.00 k |
Press releases
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
27 Dec 22
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
21 Dec 22
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
15 Nov 22
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
14 Nov 22
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
10 Nov 22